Big Pharma pools together to tackle emerging market woes

By Natalie Morrison

- Last updated on GMT

Related tags: Middle east

Big Pharma pools together to tackle emerging market woes
A host of Big Pharma firms have come together to participate in a new forum in a bid to boost patient recruitment activities in emerging markets.

Known as the Enrollment Metrix Forum , the star line-up – including Abbott, Amgen, AZ, Bayer, BMS, J&J, Lilly, Merck, Pfizer, Roche’s Genentech, Sanofi’s Genzyme, Shire, and UCB – intends to learn from the past mistakes of operating in developing industries by conducting a study in the areas.

The assessment, led by KMR Group, will look at the different approaches in Asia, Latin America, East Europe, and the Middle East and Africa and whether those approaches vary by therapy area.

It will also take into consideration how each regulatory authority operates and what is required to bring the countries into the established market.

However the forum is not simply focussed on the past – it will also consider current trends, such as what influences the recruitment strategy and performance in the regions, as well looking to the future with industry expectations.

A spokesperson for the forum also said: “The effect of different regulatory authority requirements in emerging markets will be analysed.”

Melissa Hutchens of KMR Group, said: “The Enrollment Metrix Forum realizes the role of emerging markets is one of the most important aspects currently impacting patient recruitment.

“Participants have valuable insight and are looking forward to the results of the cross industry comparison, seeing what general expectations there are in the next few years and identifying ways to improve emerging market strategy.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars